A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Baricitinib Impurity 19 - Request Quote

Picture of Baricitinib Impurity 19

Baricitinib Impurity 19

SZ CAT No:SZ-B038030
CAS No
NA
Mol.F.
C15H17N7O3S
Mol.Wt.
375.4
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Baricitinib Impurity 19 is chemically 3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidine-3-carboxamide. Baricitinib Impurity 19 is supplied with detailed characterization data compliant with regulatory guideline. Baricitinib Impurity 19 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Baricitinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Baricitinib Impurity 19

Purchase Baricitinib Impurity 19

Baricitinib Impurity 19 suppliers

Baricitinib Impurity 19 manufacturers

Baricitinib Impurity 19 price

Order Baricitinib Impurity 19

Enquire Baricitinib Impurity 19

Baricitinib Impurity 19 cost

Baricitinib Impurity 19 Supplier

Baricitinib Impurity 19 Distributor

Baricitinib Impurity 19 for Method Validation

Baricitinib Reference Standard

Baricitinib Impurity 19 for ANDA Filing

Baricitinib Impurity 19 for Forced Degradation Studies

Baricitinib Impurity 19 Identification Standards

Baricitinib Impurity 19 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,